deltatrials
Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06793215

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (Krascendo 2)

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Sponsor: Chugai Pharmaceutical

Conditions KRAS G12C Lung Cancer Non-Small Cell Lung Cancer
Interventions Carboplatin Cisplatin Divarasib Pembrolizumab Pemetrexed
Updated 14 times since 2025 Last updated: Mar 11, 2026 Started: Oct 24, 2025 Primary completion: Nov 30, 2028 Completion: Oct 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates KRAS G12C Lung Cancer and Non-Small Cell Lung Cancer and is currently actively recruiting participants. Chugai Pharmaceutical leads this study, which shows 14 recorded versions since 2025 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 2 months · monthly snapshotRecruiting

Change History

14 versions recorded

  1. Mar 2026 — Present [monthly]

    Recruiting PHASE3

  2. Feb 2026 — Mar 2026 [monthly]

    Recruiting PHASE3

  3. Jan 2026 — Feb 2026 [monthly]

    Recruiting PHASE3

  4. Dec 2025 — Jan 2026 [monthly]

    Recruiting PHASE3

  5. Nov 2025 — Dec 2025 [monthly]

    Recruiting PHASE3

▶ Show 9 earlier versions

  1. Oct 2025 — Nov 2025 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  2. Sep 2025 — Oct 2025 [monthly]

    Not Yet Recruiting PHASE3

  3. Aug 2025 — Sep 2025 [monthly]

    Not Yet Recruiting PHASE3

  4. Jul 2025 — Aug 2025 [monthly]

    Not Yet Recruiting PHASE3

  5. Jun 2025 — Jul 2025 [monthly]

    Not Yet Recruiting PHASE3

  6. May 2025 — Jun 2025 [monthly]

    Not Yet Recruiting PHASE3

  7. Apr 2025 — May 2025 [monthly]

    Not Yet Recruiting PHASE3

  8. Mar 2025 — Apr 2025 [monthly]

    Not Yet Recruiting PHASE3

  9. Feb 2025 — Mar 2025 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chugai Pharmaceutical
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Aarhus N, Denmark , Anchorage, United States , Angers, France , Arnhem, Netherlands , Athens, Greece , Atlanta, United States , Auckland, New Zealand , Aviano, Italy , Barcelona, Spain and 154 more locations